NCT01600703View on ClinicalTrials.gov

Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

August 31, 2013

Conditions
Hyperlipidemia
Interventions
DRUG

Sitagliptin

Sitagliptin, 100mg, oral, single dose

DRUG

Placebo

Placebo, oral, single dose

Trial Locations (1)

M5G 2C4

Toronto General Hospital, Toronto

All Listed Sponsors
collaborator

Merck Frosst Canada Ltd.

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT01600703 - Sitagliptin Regulation of Intestinal and Hepatic Lipoprotein Particle and Hepatic Glucose Production in Humans | Biotech Hunter | Biotech Hunter